| A |
|
A 2 ADENINE INSERTION POLYMORPHISM IN THE FVII GENE 3'UTR IS ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE BUT NOT WITH VENOUS THROMBOSIS: RESULTS OF CASE-CONTROL STUDIES
|
| Serve E., Reny J.L., Akhavan S., Emmerich J., Fischer A.M., Tapon-Bretaudière J. |
| |
|
A B3 ASP217VAL SUBSTITUTION IN A PATIENT WITH VARIANT GLANZMANN THROMBATHENIA SEVERELY AFFECTS INTEGRIN AIIBB3 FUNCTIONS
|
| D'Andrea G., D'Ambrosio R.R.D., Del Vecchio L.L.D., Amoriello A.A.A., Chinni E.E.C., Santacroce R.R.S., Sarno M.M.S., Bafunno V.V.B., Longo V.V.L., Vecchione G.G.V., Grandone E.E.G., Margaglione M.M.M. |
| |
|
A BAYESIAN APPROACH TO THE DIAGNOSIS OF TYPE 1 VON WILLEBRAND DISEASE
|
| Tosetto A., Castaman G., Rodeghiero F. |
| |
|
A BIOCHEMICAL COMPARISON OF A PHARMACEUTICALLY LICENSED S/D TREATED PLASMA WITH A UNIVERSALLY APPLICABLE DEVELOPMENT PRODUCT AND SINGLE-DONOR FFPS SUBJECTED TO METHYLENE-BLUE DYE AND WHITE-LIGHT TREATMENT
|
| Heger A., Römisch J., Svae T. |
| |
|
A CALCIUM-DEPENDENT PROTEASE CLEAVES VWF73 AT THE PEPTIDE BOND CORRESPONDING TO V1607-T1608 IN THE A2 DOMAIN
|
| Raife T.J., Bedell B., Zheng X., Montgomery R.R., Johnson G. |
| |
|
A CASE OF EWING'S SARCOMA WITH A CONGENITAL FACTOR VII DEFICIENCY
|
| Lee K., Lee J. |
| |
|
A CASE OF NORMAL PLATELET COUNT HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
|
| Lerner R.G., Hosur S., Gennarelli M. |
| |
|
A CHROMOGENIC METHOD FOR DETERMINATION OF FIXA IN PURIFIED PREPARATIONS
|
| Rosén P., Andersson M., Rosén S. |
| |
|
A CHROMOGENIC METHOD FOR QUANTITATION OF DIRECT THROMBIN INHIBITORS: A CASE STUDY
|
| Castellone D.D., Peerschke E.E.I.B. |
| |
|
A CODING SNP AT THE GPI-ATTACHMENT SITE IN THE TFPI-BETA-SPECIFIC EXON IS ASSOCIATED WITH TFPI LEVELS
|
| Vos H.L., van Hylckama Vlieg A., Sandset P.M., Rosendaal F.R. |
| |
|
A COMMON LARGE DELETION OF VWF IN GERMAN AND ITALIAN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE TYPE 3
|
| Schneppenheim R., Castaman G., Federici A.B., Franchini M., Kreuz W., Marschalek R., Obser T., Oldenburg J., Oyen F., Budde U. |
| |
|
A COMPARATIVE ANALYSIS OF THE RESPONSE TO INFLAMMATORY STIMULI OF BLOOD- AND MESENCHYMAL STEM CELLDERIVED ENDOTHELIAL PROGENITOR CELLS
|
| Liu J.W., Bounameaux H., Kruithof E.K.O. |
| |
|
A COMPARATIVE EVALUATION OF THE CS-2000I COAGULATION ANALYSER USING CLOTTING, AMIDOLYTIC AND IMMUNO-TURBIDOMETRIC ASSAYS
|
| Lawrie A.S., Kobayashi K., Tajima K., Hoshiko S., Matsuo N., Hamaguchi Y., Liesner R., Machin S.J., Mackie I.J. |
| |
|
A COMPARATIVE STUDY OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) MONITORING BY ANTI-XA LEVELS, OVERALL HAEMOSTASIS POTENTIAL (OHP) AND CALIBRATED AUTOMATED THROMBOGRAM (CAT) ASSAYS
|
| Tay L., Aboud M., Ward C.M., Morel-Kopp M.C. |
| |
|
A COMPARISON OF ANTICOAGULANTS (AC) FOR VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS (PROPH) AFTER ORTHOPEDIC SURGERY (OS) USING A CLINICAL COST-EFFECTIVENESS ANALYSIS (CEA) APPROACH
|
| Lazo-Langner A., Coyle D.A., Barrowman N.J., Ramsay T., Wells P.S., Scarvelis D., Forgie M.A., Rodger M.A. |
| |
|
A COMPARISON OF THE MEMBRANE BINDING PROPERTIES OF THE GAMMA-CARBOXY GLUTAMIC ACID PROTEINS OF BLOOD COAGULATION
|
| Krisinger M.J., Pryzdial E.L.G., MacGillivray R.T.A. |
| |
|
A COMPARISON OF TWO COMMERCIAL ADAMTS-13 ACTIVITY ASSAYS WITH A REFERENCE LABORATORY METHOD
|
| Crist R.A., Rodgers G.M. |
| |
|
A COMPREHENSIVE STUDY OF CANDIDATE GENES IN TWO SIGNALLING PATHWAYS TO IDENTIFY GENETIC VARIANTS THAT REGULATE PLATELET RESPONSIVENESS TO COLLAGEN AND ADP
|
| Earthrowl M., Eades T., Angenent W., Griffiths S., Akkerman J., Burke D., Coffey A.J., Deloukas P., Dudbridge F., Dunn R., Farndale R.W., Hoylaerts M., Hunt S., Koch K., Ranhanath V., Rice K., Stephens J., Goodall A., Ouwehand W.H., Watkins N.A., Rogers J. |
| |
|
A COVALENT REACTIVE ANTIGEN ANALOG TO FACTOR VIII REDUCES ANTIBODY PRODUCTION IN MEMORY B CELLS AFTER RE-STIMULATION WITH FVIII
|
| Smith K.C., Planque S.A., Nishiyama Y., Escobar M.A., Paul S. |
| |
|
A CRYO-ELECTRON MICROSCOPY STUDY OF RECOMBINANT FVIII BINDING TO PS LIPOSOMES
|
| Parmenter C.D.J., Cane M.C., Kemball-Cook G., Stoilova-McPhie S. |
| |
|
A DECISION SUPPORT TOOL ON HANDELD COMPUTERS TO IMPROVE DIAGNOSTIC STRATEGIES OF PULMONARY EMBOLISM IN EMERGENCY DEPARTMENTS (SPEED STUDY)
|
| Roy P., Durieux P., Perrier A., Le Gall C., Martino L., Hachelaf M., Dubart A., Liotier J., Cristiano M., Chrétien J., Meyer G. |
| |
|
A DECREASED INCIDENCE RATE OF ISCHEMIC STROKE IN PATIENTS WITH SEVERE FACTOR XI DEFICIENCY SUGGESTS THAT THE DEFICIENCY CONFERS PROTECTION
|
| Salomon O., Steinberg D.M., Koren-Morag N., Seligsohn U. |
| |
|
A DIAGNOSTIC TOOL TO SAFELY EXCLUDE DVT IN HIGH RISK GROUPS
|
| Toll D.B., Oudega R., Hoes A.W., Moons K.G.M. |
| |
|
A DIAGNOSTIC TOOL TO SAFELY EXCLUDE DVT IN PRIMARY CARE: A VALIDATION STUDY
|
| Toll D.B., Oudega R., Hoes A.W., Moons K.G.M. |
| |
|
A DIMER OF B2GLYCOPROTEIN I (B2GPI) UPREGULATES TISSUE FACTOR (TF) AND IS THROMBOGENIC IN VIVO
|
| Romay-Penabad Z., Urbanus R.T., Pennings M.T., Montiel-Manzano G., DeGroot P., Pierangeli S.S. |
| |
|
A DYNAMIC MODEL OF THE BLOOD-BRAIN BARRIER
|
| Colgan O.C., Cummins P.M., Kerrigan S.W., Cox D. |
| |
|
A FEASIBILITY STUDY OF RISK STRATIFICATION FOR RECURRENT VENOUS THROMBOSIS BY MULTIPLE SNP ANALYSIS
|
| van Hylckama Vlieg A., Rosendaal F.R., Bare L.A., Arellano A.R., Young B.A., Baglin T.P. |
| |
|
A FIBRIN-SPECIFIC MONOCLONAL ANTIBODY WITH EPITOPE LOCALIZED IN FIBRIN FRAGMENT BBETA118-134: ITS APPLICATION TO QUANTIFICATION OF SOLUBLE FIBRIN
|
| Lugovskoy E.V., Kolesnikova I.N., Gritsenko P.G., Lugovskaya N.E., Komisarenko S.V. |
| |
|
A FLUOROGENIC THROMBIN GENERATION TEST (FTGT) FOR FACTOR VIII ACTIVITY DEMONSTRATED SUCCESS OF CELL THERAPY WITH LIVER SINUSOIDAL ENDOTHELIAL CELLS (LSEC) IN HAEMOPHILIA A MICE
|
| Faulkner L., Follenzi A., Gupta S., Raut S. |
| |
|
A FUNCTIONAL AUTOMATED ASSAY FOR THROMBOMODULIN ACTIVITY IN PLASMA
|
| Rousseau A., Van Dreden P., Woodhams B.J. |
| |
|
A GADS-INDEPENDENT PATHWAY OF PLCGAMMA2 REGULATION DOWNSTREAM OF THE COLLAGEN RECEPTOR, GPVI
|
| Hughes C.E., Pedaries C., Auger J.M., McGlade J., Pearce A.C., Watson S.P. |
| |
|
A HETEROZYGOUS MUTATION OF GPIIB IN PATIENT WITH GLANZMANN THROMBASTHENIA
|
| Yu Z., Su J., Bai X., Wang Z., Ruan C. |
| |
|
A HIGH NORMAL VALUE OF PLASMA PROTEIN Z IS AN UNCOMMON FINDING IN NON-ARTERITIC ISCHEMIC OPTIC NEUROPATHY (N-AION) PATIENTS
|
| Kolaitis N.I., Felekis T., Dova L., Dokou H., Vartholomatos G., Asproudis I. |
| |
|
A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS THROMBOEMBOLISM IN CANCER PATIENTS
|
| Simanek R., Vormittag R., Alguel G., Ay C., Dunkler D., Quehenberger P., Zielinski C., Jaeger U., Pabinger I. |
| |
|
A HIGHLY-SENSITIVE PLASMA VON WILLEBRAND FACTOR (VWF):RISTOCETIN COFACTOR ACTIVITY ASSAY BY FLOW CYTOMETRY
|
| Chen D., Pruthi R.K., Nichols W.L., Heit J.A., Owen W.G. |
| |
|
A LARGE DELETION OF THE PROS1 GENE IN A DEEP VEIN THROMBOSIS PATIENT WITH PROTEIN S DEFICIENCY
|
| Yin T., Takeshita S., Sato Y., Sakata T., Shin Y., Honda S., Kawasaki T., Tsuji H., Kojima T., Madoiwa S., Sakata Y., Murata M., Ikeda Y., Miyata T. |
| |
|
A LIMITED NUMBER OF ANTI-IDIOTYPIC ANTIBODIES NEUTRALIZE FVIII INHIBITORS AND RESTORE FULL FVIII ACTIVITY IN THE PLASMA OF HAEMOPHILIA PATIENTS
|
| Gilles J.G., Grailly S.C., Jacquemin M.G., Saint-Remy J.M. |
| |
|
A MONOCLONAL ANTIBODY AGAINST PLATELET GPIBBETA INHIBITS GPIB-V-IX-DEPENDENT SIGNALLING, PROCOAGULANT ACTIVITY AND THROMBUS FORMATION UNDER FLOW PERFUSION
|
| Mangin P., Strassel C., Ravanat C., Kleitz L., Cazenave J.P., Gachet C., Lanza F. |
| |
|
A MOUSE MODEL OF HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA
|
| Motto D.G. |
| |
|
A MULTICENTER STUDY ON EARLY HEMORRHAGIC TRANSFORMATION IN ISCHEMIC STROKE: PRELIMINARY RESULTS
|
| Paciaroni M., Silvestrelli G., Ageno W., Alberti A., Lanari A., Caso V., Bertolani L., Venti M., Palmerini F., Billeci A., Biagini S., Previdi P., Agnelli G. |
| |
|
A MULTICENTRE PROSPECTIVE OPEN-LABEL STUDY ASSESSING PHARMACOKINETICS, CLINICAL EFFICACY AND SAFETY OF A TRIPLE-SECURED FIBRINOGEN CONCENTRATE: FIBRINOGENE T-I
|
| Négrier C., Borg J., Claeyssens S., De Moerloose P., Dreyfus M., Goudemand J., Gruel Y., Peyvandi F., Rothschild C., Alessi M., Scherrmann J., Waegemans T., Padrazzi B. |
| |
|
A MULTIDISCIPLINARY CLINIC FOR WOMEN WITH INHERITED BLEEDING DISORDERS
|
| Lee C.A., Chi C., Shiltag N., Khan A., Pollard D., Griffioen A., Kadir R. |
| |
|
A MURINE MODEL TO ASSESS VON WILLEBRAND FACTOR FUNCTION IN VIVO
|
| Marx I., Lenting P.J., Pendu R., Christophe O.D., Denis C.V. |
| |
|
A MUTATION IN EXON 27 OF THE VWF GENE CAUSING TYPE 2M AND TYPE 3 VON WILLEBRAND DISEASE IN THREE PATIENTS IN A FAMILY FROM THE WEST OF SCOTLAND
|
| Enayat M.S., Guilliatt A.M., Alvi A., Tait C.R., Hill F.G.H. |
| |
|
A NATIONAL FIELD STUDY OF QUALITY ASSESSMENT (QA) OF COAGUCHEK MONITORS
|
| Meijer P., Kluft C., Poller L., van der Meer F.J.M., Keown M., Ibrahim S., van den Besselaar A.M.H.P., Tripodi A., Jespersen J. |
| |
|
A NATURAL EXTRACT FROM PIPER PHILIPPINUM (2R,3R)-2-(3',4'-DEHYDROXYBENZYL)-3-(3"-4"-DIMETHOXYBENZYL)BUTYROLACTONE (PP-6) SUPPRESS FMLP-INDUCED SUPDROXIDE PRODUCTION BY INHIBITION FMLP-RECEPTOR BINDING IN HUMAN NEUTORPHIS
|
| Huang Y.J., Chen I.S., Liao C.H. |
| |
|
A NATURAL MUTATION AND SPECIFIC ARTIFICIAL DELETIONS IN THE BETA3 CYTOPLASMIC TAIL PREVENT ANTIBODY-MEDIATED ACTIVATION OF INTEGRIN ALPHAIIB-BETA3
|
| Hauschner H., Rosenberg N., Seligsohn U. |
| |
|
A NEW (I1372S) MUTATION IN THE A1 DOMAIN OF VON WILLEBRAND FACTOR ASSOCIATED WITH A TYPE 2B-LIKE VON WILLEBRAND DISEASE PHENOTYPE
|
| Sartorello F., Pontara E., Gallinaro L., Cattini M., Bertomoro A., Sztukowska M., Pagnan A., Casonato A. |
| |
|
A NEW ADAMTS13 ACTIVITY ASSAY USED WITH ANTIGEN ASSAY PROVIDES DIAGNOSTIC INFORMATION IN TTP, BLEEDING OR THROMBOSIS
|
| Guinto E., Grafos N., Fryer H., Owen J., Lawson H., Wu H.M., Greenfield R. |
| |
|
A NEW ANIMAL MODEL OF CATHETER-SELECTIVE MIDDLE CEREBRAL ARTERY THROMBO-OCCLUSIVE STROKE: DEMONSTRATION OF RAPID REPERFUSION BY LOCAL PLASMIN INFUSION
|
| Jahan R., Stewart D., Vinters H.V., Vinuela F., Vandeberg P., Marder V.J. |
| |
|
A NEW ANTITHROMBOTIC STRATEGY FOR PATIENTS WITH LONG TERM MECHANICAL CIRCULATORY SUPPORT (MCS)
|
| Boval B., Vermes E., Kirsch M., Loisance D., Drouet L. |
| |
|
A NEW CASE OF ACQUIRED GLANZMANN'S THROMBASTHENIA: COMPARATIVE EVALUATION OF THE DIAGNOSTIC VALUE OF DIFFERENT PLATELET FUNCTION TESTS
|
| Giannini S., Rossi R., Mezzasoma A., Guglielmini G., Falcinelli E., Gresele P. |
| |
|
A NEW CONVENIENT METHOD FOR FIBRINOGEN PURIFICATION BASED ON THE AFFINITY OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A TO FIBRINOGEN
|
| Liu C.Z., Cheng H.J., Chang L.Y. |
| |
|
A NEW FUNCTIONAL ASSAY FOR MEASURING PLASMA TAFIA AND ITS USE TO DEMONSTRATE TAFI ACTIVATION IN VIVO IN A PRIMATE MODEL
|
| Kim P.Y., Nesheim M.E. |
| |
|
A NEW LEU123 TO PRO MUTATION IN THE FIFTH LEUCINE-RICH REPEAT OF GLYCOPROTEIN IBALPHA IN A BERNARD-SOULIER PATIENT INDUCES DEFECTIVE SHEAR-DEPENDENT CELL ADHESION ON VON WILLEBRAND FACTOR
|
| Proulle V., Strassel C., Perrault C., Ravanat C., Baas M., Nurden P., Dreyfus M., Lanza F., Crpp . |
| |
|
A NEW LOOK AT THE PATHOPHYSIOLOGICAL PROCESSES, STAGING AND DIAGNOSIS OF SEVERE SEPSIS (TRANSLATION FROM PRECLINICAL STUDIES IN PRIMATES TO PATIENTS WITH SEVERE SEPSIS
|
| Taylor Jr. F.B. |
| |
|
A NEW MODE OF PROTHROMBIN TIME (PT) REPORTING SPECIFIC FOR LIVER DISEASES
|
| Eschwège V., Bellest L., Poupon R., Chazouillères O., Robert A. |
| |
|
A NEW MUTATION WITHIN PROTEIN Z GENE IS ASSOCIATED WITH VERY LOW PROTEIN LEVELS IN WOMEN WITH FETAL LOSS
|
| Grandone E., Colaizzo D., Cappucci F., D'Ambrosio R., Vecchione G., Margaglione M. |
| |
|
A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY BETWEEN COLLAGEN AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES
|
| Karlman M., Wiman B. |
| |
|
A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY BETWEEN FACTOR VIII AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES
|
| Karlman M., Karlsson A., Wiman B. |
| |
|
A NEW,BI-DIRECTIONAL POINT-OF-CARE TESTING-NETWORK FOR THE INR DETECTION FROM CAPILLARY WHOLE BLOOD WITH A POSITIVE PATIENT IDENTIFICATION IN ORALLY ANTICOAGULATED OUT-PATIENTS
|
| Halbmayer W., Hauer R., Köller U., Gränitz C., Heidinger M., Müller C., Sischka W. |
| |
|
A NOVEL CANDIDATE A/T789P MUTATION IDENTIFIED IN FIVE PATIENTS WITH TYPE 2N VON WILLEBRAND DISEASE FROM TWO DIFFERENT FAMILIES
|
| Rastegar Lari G., Jazebi M., Guilliatt A.M., Short P.E., Enayat M.S., Ala F.A., Chapman O., Hill F.G.H. |
| |
|
A NOVEL COMPLETE HIGH SHEAR RATE ARTERIAL THROMBOSIS AND BLEEDING MODEL IN BABOONS
|
| Roodt J.P., Lamprecht S., Silence K., Ulrichts H., Dreier T., Meiring S.M., Badenhorst P.N. |
| |
|
A NOVEL DELETION MUTATION (C.1254 DEL33BP OR C.1251DEL33BP) IN THE F13A GENE CAUSING SEVERE FACTOR XIII DEFICIENCY
|
| Ding Q., Wang X., Wu J., Chen H., Wang H. |
| |
|
A NOVEL DYSFIBRINOGENEMIA DETECTED BY ELECTROPHORESIS IN A PATIENT PRESENTING WITH FAMILIAL VENOUS THROMBOEMBOLISM
|
| Hanss M.L., Vergnes C., Chevreaud C., Ffrench P., de Mazancourt P. |
| |
|
A NOVEL FAMILY OF ALKYLATED QUINOLINES INHIBITS G PROTEIN-COUPLED RECEPTORS WITH PALMITOYLATED CYTOPLASMIC TAILS
|
| Flaumenhaft R., Dilks J.R., Sim D.S. |
| |
|
A NOVEL 'FIBRINOGEN-SPIKED' INR METHOD TO MONITOR WARFARIN IN A PATIENT WITH HYPO/DYSFIBRINOGENAEMIA (FIBRINOGEN DARLINGHURST)
|
| Low J., Kotlyar E., Joseph J. |
| |
|
A NOVEL FIBRINOLYTIC FACTOR ADIPOMIN REGULATES ADIPOSITY
|
| Seki T., Nonaka S., Okuyama K., Kimura Y., Ogihara J., Ariga T. |
| |
|
A NOVEL FLOW CYTOMETRIC METHOD FOR THE DETECTION OF RETICULATED PLATELETS BY AN ANTI-BROMODEOXYURIDINE MONOCLONAL ANTIBODY
|
| Gasparollo A., Steffan A., Tassan R., Degan M., Gattei V., De Marco L. |
| |
|
A NOVEL FUNCTION OF THE PLASMA TRANSGLUTAMINASE - COAGULATION FACTOR XIII: PROTEIN DISULFIDE ISOMERASE (PDI)
|
| Lahav J., Karniel E., Inbal A. |
| |
|
A NOVEL GPIB ALPHA BINDING PROTEIN ON STREPTOCOCCUS GORDONII INDUCES PLATELET ROLLING AT LOW SHEAR
|
| Kerrigan S.W., Jacubovics N., Meade G., Jenkinson H., Cox D. |
| |
|
A NOVEL HIGHLY PROMISING POINT-OF-CARE METHOD FOR HIV MONITORING
|
| Sanchez J.A., Thorslund S., Larsson R., Nikolajeff F., .Bergquist J. |
| |
|
A NOVEL INTEGRATED DATABASE AS REPOSITORY FOR GENETIC AND CLINICAL DATA IN ATHEROTHROMBOSIS STUDIES
|
| Rice C.M. |
| |
|
A NOVEL MECHANISM FOR CONGENITAL AFIBRINOGENEMIA BASED ON PSEUDOEXON ACTIVATION IN THE FIBRINOGEN GAMMA-CHAIN GENE
|
| Spena S., Asselta R., Platè M., Castaman G., Duga S., Tenchini M.L. |
| |
|
A NOVEL MUTATION IN EXON 10 OF FACTOR XIII SUBUNIT B
|
| Alvarado L.R., Lovejoy A.E., Nakagawa P., Hsieh L.B., Chediak J., Williams S.A., Nugent D.J. |
| |
|
A NOVEL P.ASP344VAL SUBSTITUTION IN THE FIBRINOGEN GAMMA-CHAIN CAUSES DYSFIBRINOGENEMIA ASSOCIATED WITH THROMBOSIS
|
| Le Querrec A., de MOERLOOSE P., Souibri M., Barrelier M., Gandon-Laloum S., Borel-Derlon A., Neerman-Arbez M. |
| |
|
A NOVEL P2Y12 ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST THAT INHIBITS PLATELET AGGREGATION AND THROMBUS FORMATION IN RAT AND DOG MODELS
|
| Wang Y., Vincelette J., da Cunha V., Martin-McNulty B., Mallari C., Fitch R.M., Alexander S., Islam I., Buckman B.O., Yuan S., Post J.M., Subramanyam B., Vergona R., Sullivan M.E., Dole W.P., Morser J., Bryant J. |
| |
|
A NOVEL RECOMBINANT B-DOMAIN-DELETED FACTOR VIII EXPRESSED IN A HUMAN CELL LINE
|
| Sandberg H., Agerkvist I., Lindner E., Martinelle K., Winge S. |
| |
|
A NOVEL RECOMBINANT RGD-DISINTEGRIN FROM BOTHROPS ALTERNATUS (DISBA-01) ANTAGONIZES ALPHAIIB-BETA3 AND INHIBITS THROMBOSIS
|
| Kauskot A., Cominetti M.R., Ramos O.H.P., Bechyne I., Renard J., Crépin M., Legrand C., Selistre de Araújo H.S., Bonnefoy A. |
| |
|
A NOVEL ROLE FOR CADHERIN 6 IN PLATELET FUNCTION
|
| Dunne E., Meade G., Moran N., Shields D.C., O'Neill S., Berndt M.C., Kenny D. |
| |
|
A NOVEL SINGLE-CHAIN (SCFV) ANTIBODY PHAGE-DISPLAY STRATEGY FOR THE DEVELOPMENT OF POTENTIAL ANTI-ATHEROSCLEROTIC DRUGS
|
| Eisenhardt S.U., Schwarz M., Soosairajah J., Bassler N., Peter K. |
| |
|
A PATIENT WITH A MAJOR CARBOXYPEPTIDASE N DEFICIENCY BUT WITH NORMAL PROCARBOXYPEPTIDASE U (TAFI) SERUM LEVEL
|
| Willemse J.L., Chen D., Hendriks D. |
| |
|
A PHARMACEUTICALLY LICENSED SOLVENT/DETERGENT (S/D) TREATED PLASMA AND A UNIVERSALLY APPLICABLE DEVELOPMENT PRODUCT IN TTP AND HUS: QUANTIFICATION OF ADAMTS13 AND FACTOR H LEVELS
|
| Heger A., Kannicht C., Roemisch J., Svae T. |
| |
|
A PHASE I TRIAL OF LOCALLY-DELIVERED HUMAN PLASMIN TO EVALUATE SAFETY AND THROMBOLYTIC EFFICACY IN PATIENTS WITH HEMODIALYSIS GRAFT OCCLUSION (HGO)
|
| Shlansky-Goldberg R., Baumbach G., Marder V. |
| |
|
A PHASE II DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP RANDOMIZED STUDY OF EXTENDED PROPHYLAXIS WITH ODIPARCIL FOLLOWING TOTAL HIP ARTHROPLASTY (THA)
|
| Bates S.M., Buller H., Lassen M.R., Samama M.M., Whitsett T., Fischer L., Danoff T.M., Froloshki B.S., Asbel N.R., Ginsberg J.S. |
| |
|
A PILOT STUDY TO ASSESS THE FEASIBILITY OF A MULTICENTER TRIAL FOR THE MANAGEMENT OF ASYMPTOMATIC PERSONS WITH A THROMBOPHILIA
|
| Wells P.S., Louzada M.L., Kahn S.R., Rodger M.A., Kovacs M.J., Anderson D.R., Langlois N. |
| |
|
A PILOT STUDY WITH AUTOLOGOUS BONE MARROW-DERIVED STEM CELL TRANSPLANTATION (ABSCT) IN PATIENTS WITH SEVERE PERIPHERAL ARTERIAL DISORDER (SPAD)
|
| Boda Z., Farkas K., Tóth J., Jámbor L., Soltész P., Rázsó K., Sipos T., Oláh Z., Ilonczai P., Litauszky K., Veréb Z., Rajnavölgyi É. |
| |
|
A POTENTIAL SOURCE OF ERRONEOUS RESULTS ON AUTOMATED COAGULATION ANALYSERS - AN OBSERVATIONAL STUDY
|
| Butler J.J., Wheeler M.L., Gan T.E., Malan E.H. |
| |
|
A PROPOSAL OF SCORING SYSTEM IN ASSESSMENT OF THROMBOTIC RISK IN CANCER PATIENT. A MONOCENTRIC STUDY
|
| Giordano G., Farina G., Tambaro R., Specchia M., Papini S., Piunno M., Antonelli C., Zappacosta B., Storti S. |
| |
|
A PROSPECTIVE EFFICACY AND SAFETY STUDY OF A SOLVENT-DETERGENT TREATED AND 15-NM FILTERED FACTOR VIII ADMINISTERED BY CONTINUOUS INTRAVENOUS INFUSION IN SEVERE HAEMOPHILIA A PATIENTS UNDERGOING MAJOR SURGICAL PROCEDURES (PERFACT STUDY)
|
| Stefanska E., Ladouzi A., Huszcza S., Bridey F., Meissner A., Négrier C., Scherrmann J., Waegemans T., Windyga J. |
| |
|
A PROSPECTIVE STUDY OF PATIENTS WITH CANCER WITH A SHORT ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN THE ABSENCE OF THROMBOSIS
|
| Del Carpio-Cano F.E., Zamora-Rangel D., Rosales-Manoatl M., Rivas-Gonzalez M.R., Cervera-Ceballos E., DeLa Cadena R.A. |
| |
|
A RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF LMWH ON PREGNANCY OUTCOME OF WOMEN WITH PREVIOUS PREGNANCY COMPLICATIONS. H.A.P.P.Y. STUDY
|
| Martinelli I., Battaglioli T., Mannucci P.M. |
| |
|
A RANDOMIZED, CONTROLLED, DOUBLE BLIND STUDY OF BEMIPARIN VS UNFRACTIONATED HEPARIN AS BRIDGING THERAPY OF ORAL ANTICOAGULATION THERAPY IN INVASIVE PROCEDURES OR AMBULATORY SURGERY. DESIGN OF THE BERTA STUDY
|
| Santamaría A., Fontcuberta J. |
| |
|
A RAPID METHOD FOR THE QUANTIFICATION OF THE ENANTIOMERS OF WARFARIN, PHENPROCOUMON AND ACENOCOUMAROL BY TWO DIMENSIONAL-ENANTIOSELECTIVE LIQUID CHROMATOGRAPHY/ELECTROSPRAY TANDEM MASS SPECTROMETRY
|
| Vecchione G., Tomaiuolo M., Grandone E., Cocomazzi N., Vergura P., Casetta B., Margaglione M. |
| |
|
A RARE CONGENITAL BLEEDING DISORDER: F.VII DEFICIENCY (CASE REPORT)
|
| Martinova K., Muratovska O., Glamocanin S., Antevska Z., Coneska B., Koceva S. |
| |
|
A RECOMBINANT FACTOR VIIA ANALOGUE WITH ENHANCED POTENCY, EXPRESSED BY THROMBIN GENERATION, AND PHOSPHOLIPIDS DEPENDENCY: AN IN VITRO STUDY
|
| Livnat T., Zivelin A., Kenet G., Martinowitz U. |
| |
|
A ROLE FOR 3 95105 IN FIBRINOGEN BINDING AND PLATELET AGGREGATION
|
| Haas T.A. |
| |
|
A ROLE FOR ADIPONENCTIN IN HUMAN PLATELET FUNCTION?
|
| Sim S., Chanchlani S., Kiernan A., Moran N. |
| |
|
A ROLE FOR DENSE GRANULE SECRETION IN POTENTIATION OF STORE-OPERATED CALCIUM ENTRY IN HUMAN PLATELETS
|
| Harper A.G.S., Mason M.J., Sage S.O. |
| |
|
A ROLE FOR GEMS IN PLATELET GLYCOPROTEIN IB-MEDIATED PLATELET ACTIVATION
|
| Jin W., Inoue O., Inoue K., Tamura N., Satoh K., Berndt M.C., Handa M., Goto S., Ozaki Y. |
| |
|
A ROLE FOR PLATELET ACTIVATION IN LACUNAR STROKE?
|
| Ajzenberg N., Lavallée P., Labreuche J., Dupré T., Nicaise P., Guillin M., Amarenco P. |
| |
|
A ROLE FOR SNAP-25 IN THROMBIN-INDUCED PLATELET AGGREGATION
|
| Jardin I., Redondo P.C., Salido G.M., Rosado J.A. |
| |
|
A ROLE FOR THE NA+/CA2+ EXCHANGER IN STORE-OPERATED CALCIUM ENTRY IN HUMAN PLATELETS
|
| Harper A.G.S., Sage S.O. |
| |
|
A ROLE FOR TRPV1 IN THE ACTIVATION OF HUMAN PLATELETS
|
| Sage S.O., Brownlow S.L., Harper A.G.S. |
| |
|
A ROLE OF SURFACE-BOUND PLASMINOGEN IN THE LIVER REGENERATION IN RAT
|
| Okumura N., Maeda Y., Shimonishi S., Seki T., Ariga T. |
| |
|
A ROLE OF THE ADAMTS13 GENE IN ACUTE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
|
| Meyer S.C., Largiadèr C.R., Mäder G., Sulzer I., Lämmle B., Kremer Hovinga J.A. |
| |
|
A SCREENING TEST FOR THROMBOSIS RISK FACTORS AS A MARKER OF LIVER FIBROSIS IN CHRONIC HEPATITIS C
|
| Poujol-Robert A., Eschwège V., Poupon R., Robert A. |
| |
|
A STUDY OF D-DIMER LEVELS IN CANCER PATIENTS DURING ANTINEOPLASTIC TREATMENT
|
| Garry F. |
| |
|
A STUDY OF D-DIMER LEVELS IN CANCER PATIENTS DURING ANTINEOPLASTIC TREATMENT
|
| Garry F. |
| |
|
A STUDY OF THE UTILITY OF THROMBOELASTOGRAPHY IN THE MONITORING OF ASPIRIN THERAPY
|
| Jacobson B.F., Mayne E.S., Louw S., Rachman S. |
| |
|
A SUCCESSFUL IMMUNOMODULATION-ITI RESCUE IN SEVERE HAEMOPHILIA A WITH HIGH RESPONDER INHIBITOR
|
| Tagliaferri A., Rivolta G.F., Zavota L., De Fanti A., Maurone D., Pattacini C., Izzi G. |
| |
|
A SURVEY ON POST-SURGERY OUTCOMES IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA IN A RETROSPECTIVE COHORT
|
| Ruggeri M., Rodeghiero F., Tosetto A., Castaman G., Scognamiglio F., Finazzi G., Delaini F., Micò C., Vannucchi A., Antonioli E., De Stefano V., Zà T., Gugliotta L., Tieghi A., Mazzucconi M.G., Barbui T. |
| |
|
A SURVEY ON THE PREVALENCE OF VENOUS THROMBOEMBOLIC DISEASES IN GUANGZHOU OF CHINA
|
| Feng Y., Ye X., Xie W., Zhou X., Pang Y., Liu L. |
| |
|
A SYSTEMATIC REVIEW OF THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) AND EFFECTIVENESS OF PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA (MM) RECEIVING THALIDOMIDE
|
| Wu C.M., Lee A.Y. |
| |
|
A TAILOR-MADE PEPTIDE-AFFINITY COLUMN TO IDENTIFY NOVEL BINDING PARTNERS FOR A CYTOPLASMIC MOTIF OF THE PLATELET INTEGRIN ALPHA IIB
|
| Raab M., Daxecker H., Devocelle M., Treumann A., Moran N. |
| |
|
A TECHNIQUE FOR PREVENTION OF THROMBOSIS AFTER ABDOMINAL SURGERY
|
| Sinkov S.V., Shaposhnikov S.A., Zabolotskikh I.B., Grigoriev S.V. |
| |
|
A THROMBOLYTIC REGIMEN FOR HIGH-RISK DEEP VENOUS THROMBOSIS MAY SUBSTANTIALLY REDUCE THE RISK OF POST-THROMBOTIC SYNDROME IN CHILDREN
|
| Goldenberg N.A., Durham J.D., Knapp-Clevenger R., Manco-Johnson M.J. |
| |
|
A TURKISH PATIENT WITH COMBINED DEFICIENCY OF VITAMIN K-DEPENDENT CLOTTING FACTORS
|
| Ucar Albayrak C., Caliskan U. |
| |
|
A TYPE VICENZA-LIKE VON WILLEBRAND DISEASE NOT ASSOCIATED WITH VWF GENE MUTATION NOR ANTI-VWF ANTIBODIES
|
| Sztukowska M., Gallinaro L., Daidone V., Pontara E., Sartorello F., Bertomoro A., Pagnan A., Casonato A. |
| |
|
A VERY RARE CONGENITAL BLEEDIND DISORDER-BERNARD SOULIER SYNDROME, FOUND IN A FAMILY IN MACEDONIA
|
| Stankovic S.G., Ivanovski M., Stojanovic A. |
| |
|
A WHOLE BLOOD CLOTTING METHOD MEASURING EX VIVO EFFECTS OF RFVIIA AND FVIII IN HAEMOPHILIA BLOOD
|
| Larsen L.F., Ezban M., Hedner U., Nicolaisen E.M., Tengborn L. |
| |
|
ABCIXIMAB-DEPENDENT THROMBOCYTOPENIA IN PATIENTS WITH ACUTE CORONARY SYNDROMES CAN OCCUR BY DIFFERENT MECHANISMS
|
| Lajus S., Jais C., Coste P., Binet A., Lefebvre J., Clofent Sanchez G., Nurden A.T., Nurden P. |
| |
|
ABDOMINAL AORTIC ANEURYSM AND CAROTID ARTERY DISEASE: GENE EXPRESSION PROFILING OF TWO ATHEROSCLEROTIC DISEASES
|
| Giusti B., Rossi L., Lapini I., Lavitrano M.L., Biasi G.M., Pulli R., Pratesi G., Pratesi C., Abbate R., Gensini G.F. |
| |
|
ABNORMAL MEGAKARYOCYTE MATURATION WITH IMPAIRED PROPLATELET FORMATION IN A MOUSE MODEL OF BERNARD-SOULIER SYNDROME
|
| Strassel C., Eckly A., Leon C., Petitjean C., Freund M., Cazenave J.P., Gachet C., Lanza F. |
| |
|
ABNORMAL PATTERN FOR FVIII GENE INTRON 1 INVERSION IN ONE BRAZILIAN FAMILY
|
| Pio S.F., Zouain D., Correa G., Rezende S.M. |
| |
|
ABNORMAL PLATELET FUNCTION IS COMMON IN PEDIATRIC CONGENITAL CARDIAC SURGERY PATIENTS
|
| Boshkov L.K., Person T., Welke K., Martchenke J., Ungerleider R. |
| |
|
ABNORMALITIES IN THE SEROTONIN METABOLISM: A PATHOGENIC HYPOTHESIS FOR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
|
| Drouet L., Paques M., Peoc'h K., Callebert J., Krivosic V., Boval B., Launay J., Gaudric A. |
| |
|
ABSENCE OF ADAMTS13 ON A VWF DEFICIENT BACKGROUND IS NO LONGER PROTHROMBOTIC IN A MURINE MODEL OF ARTERIAL THROMBOSIS
|
| Chauhan A.K., Walsh M.T., Motto D.G., Ginsburg D., Wagner D.D. |
| |
|
ABSENCE OF INHIBITOR FORMATION IN PREVIOUSLY TREATED HAEMOPHILIA A PATIENTS TREATED WITH A DOUBLE VIRUS INACTIVATED, PLASMA DERIVED FACTOR VIII/VWF CONCENTRATE IN PROSPECTIVE CLINICAL STUDIES
|
| Windyga J., Klukowska A., Jansen M., Feddern J. |
| |
|
ACCELERATED ATHEROGENESIS AND NEOINTIMA FORMATION IN HEPARIN COFACTOR II DEFICIENT MICE
|
| Vicente C.P., He L., Tollefsen D.M. |
| |
|
ACCEPTABILITY AND EFFICACY OF PATIENT SELF-TESTING IN PATIENTS NEW TO THE ANTICOAGULATION CLINIC
|
| Longair I., Gardiner C., Pescott M.A., Erwin H., Machin S.J., Cohen H. |
| |
|
ACCURACY AND COST EVALUATION OF A PORTABLE INR MONITOR
|
| Paoletti O., Alatri A., Morstabilini G., Fugazza A., Testa S. |
| |
|
ACCURACY AND USEFULNESS OF A CLINICAL PREDICTION RULE AND D-DIMER TESTING IN EXCLUDING DEEP VEIN THROMBOSIS (DVT) IN CANCER PATIENTS
|
| Carrier M., Lee A., Bates S.M., Anderson D.R., Wells P.S. |
| |
|
ACCURACY OF THE COAGUCHEK XS FOR POC INR IN CHILDREN REQUIRING WARFARIN
|
| Bauman M.E., Black K., Howlettt-Clyne S.M., Massicotte M. |
| |
|
ACCURATE BEDSIDE DIAGNOSTIC KIT FOR DETERMINING HEMOPHILIA A AND
|
| Chuansumrit A., Pongtanakul B., Chotsuppakarn S., Sasanakul W., Kadegasem P., Kitpoka P., Bejrachandra S. |
| |
|
ACETYLSALICYLIC ACID (ASA) RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE (IHD) AS BIOINDICATOR OF THE TREATMENT STRATEGY
|
| Maly J., Pecka M., Pudil R., Maly R., Dulicek P., Gregor J., Vokurkova D. |
| |
|
ACL TOP PERFORMANCE IN ROUTINE COAGULATION TESTING
|
| Milos M., Coen Herak D., Kuric L., Horvat I., Zadro R. |
| |
|
ACQUIRED AND INHERITED PREDISPOSING CONDITIONS IN PATIENTS WITH RETINAL VEIN OCCLUSION
|
| Di Capua M., Coppola A., Loffredo M., Albisinni R., Tufano A., Cimino E., Di Minno M.N.D., Cirillo F., Cerbone A.M. |
| |
|
ACQUIRED FACTOR VIII INHIBITOR: REPORT FROM THE REGIONAL HAEMOPHILIA CENTRE
|
| Smejkal P., Bulikova A., Matyskova M., Mayer J., Penka M. |
| |
|
ACQUIRED FACTOR VIII INHIBITORS IN NON-HEMOPHILIC PATIENTS: CLINICAL EXPERIENCE OF 16 CASES
|
| Zheng C.C., Wu J.S. |
| |
|
ACQUIRED FACTOR XIII INHIBITOR: A CASE REPORT
|
| Oliveira M.H.C.F., Gadelha T.T.G., Oliveira N.N.C.O. |
| |
|
ACQUIRED HAEMOPHILIA A WITH INHIBITOR - CASE REPORT
|
| Stasko J., Kubisz P., Dobrotova M., Ivankova J., Holly P., Bartosova L., Chudy P. |
| |
|
ACQUIRED HEMOPHILIA A IN A PATIENT WITH HYDATID DISEASE: A CASE REPORT
|
| Vega-Ostertag M.E., Suárez Gonzales L., Pagani F. |
| |
|
ACQUIRED HEMOPHILIA IN AN HIV PATIENT
|
| Mingot M.E., Ballesteros I., Perez de Pedro I., Castaño M., Causse M., Heiniger A. |
| |
|
ACQUIRED HEMOPHILIA: ANALYSIS OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY
|
| Sood S.L., Shihong I., Swavola J., Thielke R., Armstrong A.E., Gill J.C., Kessler C.M., Konkle B.A., HTRS Registry Investigators |
| |
|
ACQUIRED RESISTANCE TO ACTIVATED PROTEIN C (APC) IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET)
|
| Marchetti M., Castoldi E., Spronk H.M.H., Balducci D., Barbui T., Rosing J., ten Cate H., Falanga A. |
| |
|
ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH SYSTEMIC LUPUE ERYTHEMATOSUS
|
| b. d. Karim F.A., Ayob Y. |
| |
|
ACTIVATED COAGULATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
|
| Negaard H.F.S., Iversen P.O., Ostenstad B., Iversen N., Holme P.A., Sandset P.M. |
| |
|
ACTIVATED FACTOR XII TYPE A INDEPENDENTLY PREDICTS 12 MONTH MORTALITY IN CHEST PAIN PATIENTS
|
| Pönitz V., Brugger-Andersen T., Pritchard D., Grundt H., Staines H., Nilsen D.W.T. |
| |
|
ACTIVATED PLATELETS ENHANCE THE ADHERENCE TO AND INVASION OF ENDOTHELIAL CELLS BY STAPHYLOCOCCUS AUREUS
|
| Niemann S., Heilmann C., Peters G., Van Aken H.K., Kehrel B.E. |
| |
|
ACTIVATED PLATELETS INDUCE TISSUE FACTOR PATHWAY INHIBITOR IN PERIPHERAL BLOOD MONOCYTES
|
| Wright J.R., Appleby J.A., Chan D., Goodall A.H. |
| |
|
ACTIVATED PROTEIN C
|
| Griffin J.H., Fernàndez J.A., Gale A.J., Mosnier L.O. |
| |
|
ACTIVATED PROTEIN C (APC) REQUIRES RESIDUES 176-178 FOR NORMAL ANTICOAGULANT, ANTI-APOPTOTIC AND ANTI-INFLAMMATORY ACTIVITIES
|
| Yang X.V., Mosnier L.O., Griffin J.H. |
| |
|
ACTIVATED PROTEIN C ATTENUATES LIPOPOLYSACCHARIDE-INDUCED ACTIVATION OF CELL DEATH AND TUMOUR NECROSIS FACTOR-ALPHA PRODUCTION IN MURINE MICROGIAL CELLS
|
| Egrilmez M., Cavdar Z., Aykan S., Genc S., Genc K., Guner G. |
| |
|
ACTIVATED PROTEIN C HAS BOTH INTRACELLULAR AND EXTRACELLULAR EFFECTS ON BREAST CANCER AND ENDOTHELIAL CELL MIGRATION
|
| Beaulieu L.M., Gramling M., Church F.C. |
| |
|
ACTIVATED PROTEIN C INCREASES TISSUE FACTOR EXPRESSION ON HUMAN UMBILICAL ENDOTHELIAL CELL BY EPCR-DEPENDENT BUT PAR-1-INDEPENDENT MANNER
|
| Uchiba M., Yonemura Y., Kaun C., Wojta J., Okajima K., Ando Y., Mitsuya H., Binder B.R. |
| |
|
ACTIVATED PROTEIN C INHIBITION BY PROTEIN C INHIBITOR IS NOT ACCELERATED BY THE SYNTHETIC PENTASACCHARIDE FONDAPARINUX
|
| Müller J., Page S., Madlener K., Pötzsch B. |
| |
|
ACTIVATED PROTEIN C LEADS TO CELL SURFACE ACCUMULATION OF CLEAVED PAR1 AND SUPPORTS PROTECTIVE SIGNALING EVEN IN THE PRESENCE OF THROMBIN
|
| Schuepbach R.A., Feistritzer C., Lenta R.E., Riewald M. |
| |
|
ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE, RECOMBINANT FACTOR VIII AND FACTOR IX REVERSE PROLONGED CLOTTING TIME INDUCED BY DU-176B, A DIRECT FACTOR XA INHIBITOR, IN HUMAN PLASMA
|
| Morishima Y., Fukuda T., Honda Y., Shibano T. |
| |
|
ACTIVATION LOOP 3 AND THE 170 LOOP INTERACT IN THE MOST ACTIVE CONFORMATION OF FACTOR VIIA
|
| Persson E., Olsen O.H. |
| |
|
ACTIVATION OF ANTITHROMBIN BY SEQUENTIAL DELETION OF TWO AND THREE SUCCESSIVE RESIUES IN THE C-TERMIANL REGION OF THE REACTIVE CENTER LOOP
|
| Koide T., Shoya Y. |
| |
|
ACTIVATION OF BLOOD COAGULATION IN AB0-COMPATIBLE BLOOD BY MULTIPOTENT MESENCHYMAL STROMAL CELLS
|
| Rasmusson I., Elgue G., Korsgren O., Nilsson B., Le Blanc K. |
| |
|
ACTIVATION OF FACTOR XII BY MISFOLDED PROTEIN AGGREGATES; IMPLICATIONS FOR CONTACT ACTIVATION
|
| Maas C., Bouma B., Hammarström P., Bouma B.N., Gebbink M.F.B.G. |
| |
|
ACTIVATION OF HUMAN LUNG ENDOTHELIAL CELLS INDUCES THE RELEASE OF A FVIII STORAGE POOL
|
| Jacquemin M.G., Lavend'homme R., Saint-Remy J., Peerlinck K. |
| |
|
ACTIVATION OF HUMAN PLATELETS BY MISFOLDED PROTEINS
|
| Herczenik E., Bouma B., Korporaal S.J.A., Strangi R., Zeng Q., Gros P., Van Eck M., Van Berkel T.J.C., Gebbink M., Akkerman J.N. |
| |
|
ACTIVATION OF INTRAVASCULAR COAGULATION DURING HEMODIALYSIS WITH DIFFERENT HEPARINS: A CROSS-OVER STUDY
|
| Naumnik B., Pawlak K., Mysliwiec M. |
| |
|
ACTIVATION OF PLATELETS BY A VON WILLEBRAND FACTOR-BINDING PEPTIDE SEQUENCE PRESENT IN COLLAGEN III
|
| Maddox B.D., Farndale R.W. |
| |
|
ACTIVATION OF PLATELETS BY DIMERIC 2-GLYCOPROTEIN I REQUIRES SIGNALING VIA BOTH GLYCOPROTEIN IBalpha AND APOLIPOPROTEIN E RECEPTOR 2'
|
| Urbanus R.T., Pennings M.T.T., Derksen R.H.M.W., de Groot P.G. |
| |
|
ACTIVE CONFORMATION OF VON WILLEBRAND FACTOR IN TTP IS NOT RESTRICTED TO ULTRA-LARGE MULTIMERS
|
| Groot E., de Groot P.G., Fijnheer R., Lenting P.J. |
| |
|
ACTIVE SITE INHIBITED FACTOR VIIA HAS A PROTECTIVE ROLE IN RENAL ISCHEMIA/REPERFUSION INJURY VIA ANTI-INFLAMMATORY MECHANISMS
|
| Loubele S.T.B.G., Leenders P., van Oerle R., Hamulyak K., Buurman W.A., Spronk H.M.H., van der Voort D., ten Cate H. |
| |
|
ACTIVE SITE INHIBITED FACTOR VIIA REDUCES MYOCARDIAL INFARCT SIZE AFTER ISCHEMIA/REPERFUSION INJURY IN MICE VIA TISSUE FACTOR/NFKAPPAB-MEDIATED MECHANISMS
|
| Loubele S.T.B.G., Leenders P., van Oerle R., Hamulyak K., Spek C.A., Spronk H.M.H., van der Voort D., ten Cate H. |
| |
|
ACTIVE SITE-INHIBITED RFVIIA BLOCKS PLATELET STRING FORMATION ON INTACT ENDOTHELIUM ACTIVATED WITH TNF-ALPHA AND SHIGA TOXIN-1
|
| Grabowski E.F., Nestoridi E., Kushak R., Ingelfinger J.R. |
| |
|
ACTIVITIES AND POLYMORPHISMS OF ADAMTS13 IN THE JAPANESE GENERAL POPULATION
|
| Kokame K., Kokubo Y., Okayama A., Miyata T. |
| |
|
ACUTE CORONARY STENT THROMBOSIS IN A PATIENT WITH SEVERE HAEMOPHILIA ON DUAL ANTIPLATELET THERAPY
|
| Rusen L., Lambert C., Hermans C. |
| |
|
ACUTE CORONARY SYNDROME AND MEAN PLATELET VOLUME
|
| Quintana M., Sevilla J., Sánchez M., Taberna M. |
| |
|
ACUTE EFFECT OF STATINS ON THE REGULATION AND EXPRESSION OF CANDIDATE GENES (CD36, MMP-9 AND IL-8) IN ATHEROSCLEROSIS IN HIV-INFECTED PATIENTS
|
| De Lorenzo F., Martin J., Boffito M., McGregor J. |
| |
|
ACUTE THROMBOSIS IN A PATIENT WITH ACQUIRED FVIII INHIBITOR: CASE REPORT
|
| Serpa M.G., Zeinad A.K., Villaça P.R., Park M., Bassitt R.P., Chamone D.F., D'Amico E.A. |
| |
|
ADAMTS 13 IN NON-THROMBOTIC THROMBOCYTOPENIC PURPURA CONDITIONS
|
| Scully M., Liesner R., Burgess C., Lawrie A., Machin S.J. |
| |
|
ADAMTS13 ACTIVITY AND AUTOANTIBODIES IN IDIOPATHIC TTP: RESULTS FROM THE SERF-TTP GROUP
|
| Zakarija A., Kwaan H., Bandarenko N., Cursio J., Pandey D., Weiss I., Buffie C., Tevar A., Yarnold P., Raife T., Ortel T., Bennett C.L. |
| |
|
ADAMTS-13 ACTIVITY, ANTIGEN AND INHIBITOR ANTIBODIES IN TTP PATIENTS A SINGLE CENTER EXPERIENCE
|
| Sarig G., Dann E.J., Tennenbaum G., Rowe J.M., Brenner B. |
| |
|
ADAMTS13 AND VON WILLEBRAND FACTOR IN THE PATIENTS WITH DIC
|
| Ono T., Watanabe S., Furusaki F. |
| |
|
ADAMTS13 AND VWF IN PEDIATRIC PATIENTS WITH SEVERE MENINGOCOCCAL SEPSIS
|
| Bongers T.N., Emonts M., de Maat M.P.M., de Groot R., Hazelzet J.A., Leebeek F.W.G. |
| |
|
ADAMTS13 LEVELS ARE ASSOCIATED WITH THE RISK OF ARTERIAL THROMBOSIS IN YOUNG SUBJECTS
|
| Bongers T.N., de Bruijne E.L.E., Dippel D.W.J., Deckers J.W., Poldermans D., de Maat M.P.M., Leebeek F.W.G. |
| |
|
ADAMTS13 RELATED MARKERS IN PLASMA FROM PATIENTS WITH TTP
|
| Wada H., Kobayashi T., Matsumoto T., Nobori T., Abe Y. |
| |
|
ADAMTS13 STRUCTURE AND FUNCTION
|
| Soejima K. |
| |
|
ADAMTS-13 WITHIN THROMBUS DOWN-REGULATES THROMBUS FORMATION UNDER FLOW CONDITIONS
|
| Moriguchi-Goto S., Yamashita A., Tamura N., Soejima K., Nakagaki T., Goto S., Asada Y. |
| |
|
ADDITION OF PRION REDUCTION FACTORS FROM SINGLE STEP EXPERIMENTS MAY OVERESTIMATE MANUFACTURING PROCESS CLEARANCE CAPABILITY
|
| Schäfer W., Pham H., Martinelli T., Gröner A. |
| |
|
ADIPOCYTOKINES AND VASCULAR ENDOTHELIUM IN DIABETIC AND NON-DIABETIC PERITONEALLY DIALYZED PATIENTS
|
| Malyszko J., Malyszko J.S., Pawlak K., Mysliwiec M. |
| |
|
ADIPONECTIN INDUCES AGGREGATION AND ACTIVATION OF HUMAN PLATELETS BY A PHOSPHATIDYL INOSITOL 3-KINASE-DEPENDENT MECHANISM
|
| Naseem K.M., Riba R. |
| |
|
ADP INDUCED TF PRODUCTION BY FORMATION OF PLATELET-MONOCYTE AGGREGATES IS NOT EFFECTED BY DIRECT THROMBIN INHIBITORS
|
| Christersson C., Siegbahn A. |
| |
|
AGE- AND GENDER-RELATED DIFFERENCES OF PLASMA PROTHROMBIN ACTIVITY LEVELS
|
| Sakata T., Okamoto A., Morita T., Kokubo Y., Sato K., Okayama A., Tomoike H., Miyata T. |
| |
|
AGE-DEPENDENT INCREASED ARTERIAL STIFFNESS IS ASSOCIATED WITH COMPOSITE CHANGES IN PRO- AND ANTI-COAGULANT REACTIONS IN SUBCLINICAL ATHEROSCLEROSIS
|
| Kearney-Schwartz A., Benetos A., Membre A., Lecompte T., Max J.P., Labat C., Thornton S.N., Lacolley P., Regnault V. |
| |
|
AGE-RELATED CHANGES BY ASPARAGINASE ON COAGULATION AND FIBRINOLYSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
|
| Appel I.M., Hop W.C.J., Pieters R. |
| |
|
AGE-RELATED REFERENCE RANGES FOR NEOPLASTINE R (PT) AND CEPHASCREEN (APTT) IN HEALTHY CHILDREN
|
| Summerhayes R., Ignjatovic V., Hall M., Monagle P. |
| |
|
AGE-RELATED REFERENCE RANGES FOR TAFI AND FIBRIN MONOMERS IN HEALTHY CHILDREN
|
| Summerhayes R., Ignjatovic V., Hall M., Monagle P. |
| |
|
AGGREGATION TEST FOR DETECTION CLOPIDOGREL RESISTANCE
|
| Maliskova J., Slavik L., Krcova V., Novak P., Galuszka J., Hutyra M. |
| |
|
AIR TRAVEL AND VENOUS THROMBOSIS: A SYSTEMATIC REVIEW
|
| Kuipers S., Schreijer A.J.M., Cannegieter S.C., Rosendaal F.R., Middeldorp S. |
| |
|
AIRWAY OBSTRUCTION CAUSED BY HEMORRHAGE IN PATIENTS (PTS) WITH INHIBITOR HEMOPHILIA
|
| Galstyan G.M., Zorenko V.Y., Malofeev V.N., Vasiliev S.A., Vasiliev D.V., Polyanskaya T.Y. |
| |
|
AKT ACTIVATION BY PHOSPHAPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE IN HUMAN PLATELETS IS DEPENDENT ON EXTRACELLULAR CA2+
|
| Kassouf N., Ambily A., Authi K.S. |
| |
|
ALANINE AMINOTRANSFERASE, ATHEROTHROMBOTIC RISK FACTORS AND METABOLIC SYNDROME IN SOUTH ASIANS
|
| Kain K., Scott E.M., Carter A.M. |
| |
|
ALCOHOL CONSUMPTION IS NOT ASSOCIATED WITH FIBRINOGEN IN A LARGE POPULATION OF AFRICAN BLACKS
|
| Hoekstra T., Vorster H., Kruger A. |
| |
|
ALL PROTEIN S (PS) EPIDERMAL GROWTH FACTOR LIKE DOMAINS (EGFS) SIGNIFICANTLY PARTICIPATE TO ACTIVATED PROTEIN C (APC) COFACTOR ACTIVITY
|
| Gandrille S., Saposnik B., Borgel D., André E., Gaussem P., Aiach M. |
| |
|
ALLELIC FREQUENCY AND MINOR VARIATIONS OF THE FACTOR V R2 HAPLOTYPE IN JAPANESE POPULATION
|
| Yamazaki T., Okada H., Toyoda Y., Kunishima S., Hamaguchi M., Saito H., Kojima T. |
| |
|
ALLOSTERIC REGULATION OF PROTHROMBIN ACTIVATION BY FACTOR VA
|
| Barhoover M.A., Bukys M.A., Orban T., Erdogan E., Kalafatis M. |
| |
|
ALL-TRANS RETINOIC ACID (ATRA) INHIBITS ENDOTHELIAL ANGIOGENESIS INDUCED BY TUMOR CELLS AND STANDARD FACTORS
|
| Russo L., Marchetti M., Vignoli A., Balducci D., Falanga A. |
| |
|
ALPHA V SUPPRESSION BY SIRNA AUGMENTS OR INHIBITS VEGF AND VEGFR-2 EXPRESSION DEPENDING ON THE ORIGIN OF ENDOTHELIAL CELLS
|
| Dardik R., Livnat T., Zivelin A., Rosenberg N., Seligsohn U. |
| |
|
ALPHA-1-ANTITRYPSIN IS THE MOST ABUNDANT PROTEIN NON-COVALENTLY BOUND TO THE FIBRIN MATRIX OF A PLASMA CLOT
|
| Rijken D.C., Dirkx S.P.G., Leebeek F.W.G. |
| |
|
ALTERATIONS OF HEMOSTATIC PARAMETERS IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION
|
| Han Y., Lu X., Wu D., Sun A., Wang Z., Ruan C. |
| |
|
ALTERATIONS OF INFLAMMATORY AND HAEMOSTATIC INDICES IN RHEUMATIC DISEASES
|
| Gu J. |
| |
|
ALTERED BINDING OF PURIFIED TYPE 2M VICENZA VON WILLEBRAND FACTOR TO PLATELET RECEPTOR ALPHAIIBBETA3 AND GPIB-V-IX COMPLEX
|
| Cozzi M.R., Castaman G., Mazzucato M., Steffan A., Battiston M., Rodeghiero F., De Marco L. |
| |
|
ALTERED ULTRALARGE VON WILLEBRAND FACTOR LEVELS AND ADAMTS-13 ACTIVITY AFFECT RESIDUAL PLATELET REACTIVITY IN HIGH RISK VASCULAR PATIENTS ON DUAL ANTIPLATELET THERAPY
|
| Marcucci R., Cesari F., Cinotti S., Gori A., Paniccia R., Gensini G., Abbate R. |
| |
|
ALTERNATION OF VON WILLEBRAND FACTOR AND ADAMTS13 ACTIVITY AND ITS CLINICAL SIGNIFICANCE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME
|
| Koyama N., Makinodann K., Tamaki S., Fukuoka A., Hamada K., Matsumoto M., Fujimura Y., Kimura H. |
| |
|
ALTERNATIVE ANTICOAGULATION WITH DANAPAROID IN TWO PREGNANCIES IN A PATIENT WITH FORMER HIT, THROMBOPHILIA, A HISTORY OF VENOUS THROMBOSIS AND RECURRENT PREGNANCY LOSSES
|
| Schindewolf M., Linnemann B., Klaeffling C., Lindhoff-Last E. |
| |
|
ALTERNATIVE ANTICOAGULATION WITH FONDAPARINUX IN PREGNANT PATIENTS WITH HEPARIN-INTOLERANCE
|
| Schindewolf M., Daemgen-von-Brevern G., Mani H., Lindhoff-Last E. |
| |
|
ALTERNATIVE SPLICING AND NONSENSE-MEDIATED DECAY IN THE F5 GENE
|
| Dall'Osso C., Duga S., Locatelli N., Peyvandi F., Tenchini M.L., Asselta R. |
| |
|
AMBLYOMIN-X IN CULTURED CANCER CELLS: CITOTOXICITY AND CELL CYCLE EFFECTS
|
| Chudzinski-Tavassi A.M., Ventura J.S., Lapetina D.L., De-Sá-Júnior P.L., Batista I.F.C., Ramos O.H.P. |
| |
|
AN ABNORMAL MRNA SPLICING IS ASSOCIATED WITH THE A3 HAPLOTYPE OF THE EPCR GENE PROCR: A POSSIBLE NEW CONTRIBUTOR TO PLASMA SOLUBLE EPCR LEVELS
|
| Saposnik B., Lesteven E., Lokajczyk A., Emmerich J., Esmon C.T., Aiach M., Gandrille S. |
| |
|
AN ANTI-VON WILLEBRAND'S FACTOR A1 DOMAIN APTAMER INHIBITS ARTERIAL THROMBOSIS INDUCED BY ELECTRICAL INJURY IN CYNOMOLGUS MACAQUES
|
| Rottman J.B., Gilbert M., Marsh H.N., Boomer R.M., Fraone J.M., Makim A., Lewis S.D., Cai L., McCauley T., Hutabarat R., Diener J.L. |
| |
|
AN ASSESSMENT OF THE EFFECTIVENESS OF INFERIOR VENA CAVA FILTERS IN PREVENTION OF PULMONARY EMBOLISM BASED UPON DEMONSTRATION OF TRAPPED EMBOLUS AT THE TIME OF FILTER RETRIEVAL
|
| McKenzie S.C., Leggett D., Neels M., Harper J., Gibbs H. |
| |
|
AN ASSOCIATION OF VICENZA AND NORMANDY VARIANTS VON WILLEBRAND DISEASE (VWD)
|
| Keller L., Woods A., Kempfer A., Farias C., Sanchez-Luceros A., Grosso S., Lazzari M. |
| |
|
AN AUDIT OF THROMBOPHILIA SCREENING IN A SINGLE PAEDIATRIC TERTIARY REFERRAL CENTRE
|
| Watt S.G., Natarajan S., Wynn R., Will A., Grainger J. |
| |
|
AN AUSTRALIAN EXPERIENCE OF RETRIEVABLE INFERIOR VENA CAVA FILTERS IN PATIENTS WITH INCREASED RISK OF THROMBOEMBOLIC DISEASE
|
| McKenzie S.C., Leggett D., Neels M., Harper J., Gibbs H. |
| |
|
AN EF-HAND MUTATION IN STIM1 CAUSES PREMATURE PLATELET ACTIVATION AND BLEEDING IN MICE
|
| Braun A., Grosse J., Varga-Szabo D., Beyersdorf N., Muhlstedt S., Schulze H., Kerkau T., Nieswandt B. |
| |
|
AN ENU MUTAGENESIS SCREEN FOR DOMINANT GENETIC MODIFIERS OF THROMBOSIS IN THE FACTOR 5 LEIDEN MOUSE
|
| Westrick R.J., Manning S.L., Winn M.E., Stotz G.M., Sanford E., Ginsburg D. |
| |
|
AN EVALUATION OF A PHARMACY INPATIENT ANTICOAGULATION SERVICE IN GENERAL & EMERGENCY MEDICINE
|
| Madhani M., Torrens N., Varma G., Duggan C. |
| |
|
AN EVALUATION OF AN ARGATROBAN DOSE TITRATION NOMOGRAM
|
| Koerber J.M., Mattson J.C., Kennedy M., Smythe M.A. |
| |
|
AN EVALUATION OF SINGLE PORTION REAGENT VIALS FOR ROTEM ANALYSIS
|
| Rahe-Meyer N., Winterhalter M., Lang T., Solomon C. |
| |
|
AN EX VIVO PERFUSION MODEL TO STUDY THE TREATMENT OF THROMBOTIC MICROANGIOPATHY DURING PIG-TO-HUMAN XENOGENIC KIDNEY TRANSPLANTATION
|
| Tiede A., Ramackers W., Friedrich L., Schüttler W., Kalippke K., Horter S., Piepenbrock S., Klempnauer J., Ganser A., Winkler M. |
| |
|
AN EXTERNAL QUALITY ASSESSMENT PROGRAMME FOR PATIENT SELF-TESTING FOR MONITORING INRS- 2 YEARS OF RESULTS
|
| Kitchen D.P., Kitchen S., Jennings I., Woods T.A.L., Walker I.D. |
| |
|
AN IAP RETROTRANSPOSON IN MOUSE ADAMTS13 GENE GENERATES ADAMTS13 VARIANTS LESS EFFECTIVE IN CLEAVING VWF MULTIMERS
|
| Zhou W., Bouhassira E.E., Tsai H. |
| |
|
AN IN VIVO RISK/BENEFIT COMPARISON OF THE EFFECTS OF RIVAROXABAN AN ORAL, DIRECT FACTOR XA INHIBITOR WITH THROMBIN INHIBITORS, WARFARIN AND CLOPIDOGREL
|
| Perzborn E., Arndt B., Fischer E., Harwardt M., Lange U., Trabant A. |
| |
|
AN INCREASE OF CELL LETHALITY IN IRRADIATED VASCULAR ENDOTHELIUM AND PROBLEM OF HAEMOSTASIS
|
| Fedortseva R.F., Aleksanin S.S., Bychkovskaya I.B. |
| |
|
AN INTEGRATED APPROACH TO EFFECTIVE PATHOGEN REDUCTION FOR A PLASMA-DERIVED VWF/FVIII CONCENTRATE
|
| Nowak T., Schäfer W., Gröner A. |
| |
|
AN OBSERVATIONAL COHORT OF PATIENTS UNDERGOING FONDAPARINUX THROMBOPROPHYLAXIS AFTER ROUTINE ORTHOPEDIC SURGERY (OS): THE ARISTOTE STUDY
|
| Delecroix M. |
| |
|
AN OBSERVATIONAL STUDY OF SUCROSE-FORMULATED RECOMBINANT FACTOR VIII FOR JAPANESE PATIENTS WITH HEMOPHILIA A
|
| Delumeau J.C. |
| |
|
AN ULTRA SENSITIVE ASSAY FOR THE QUANTIFICATION OF GPVI SHEDDING IN HUMAN PLASMA
|
| Takizawa H., Matsumoto Y., Concepcion A., Gong X., Lockyer S., Kambayashi J., Tandon N.N. |
| |
|
ANALYSING PLATELET FUNCTION FOR FUNCTIONAL GENOMIC STUDIES
|
| Jones C.I., Garner S.F., Agenent W., Bernard A., Berzuini C., Burns P., Farndale R.W., Hogwood J., Koch K., Rankin A., Rice C., Stephens J., Tom B.D., Walton J., Dudbridge F., Ouwehand W.H., Goodall A.H. |
| |
|
ANALYSIS OF ADAMTS13 IN PATIENTS WITH COLLAGEN DISEASE-ASSOCIATED TMAS
|
| Matsuyama T., Matsumoto M., Isonishi A., Uemura M., Inokuma S., Fujimura Y. |
| |
|
ANALYSIS OF AFFINITY OF KNOB-HOLE INTERACTIONS RESPONSIBLE FOR FIBRIN POLYMERIZATION
|
| Geer C.B., Tripathy A., Schoenfisch M.H., Lord S.T., Gorkun O. |
| |
|
ANALYSIS OF DISCREPANT ASSAY-DETERMINED ACTIVITY LEVELS OF FACTOR VIII ASSOCIATED WITH R531H MUTATION
|
| Inaba H., Yatomi Y., Shinozawa K., Otaki M., Suzuki T., Amano K., Fukutake K. |
| |
|
ANALYSIS OF EFFECTS OF METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) AND THYMIDYLATE SYNTHASE ENHANCER REGION (TSER) POLYMORPHISMS ON HOMOCYSTEINE CONCENTRATION AND RECURRENT SPONTANEOUS ABORTION IN KOREANS
|
| Kim N., Choi D., Kang M., Oh D. |
| |
|
ANALYSIS OF FOLATE-RELATED GENES FOR ASSOCIATION WITH PLASMA HOMOCYSTEINE LEVEL IN A SNP-MICROARRAY APPROACH
|
| Vemeulen S.H.H.M., Franke B., Coenen M.J., Schijvenaars M., Scheffer H., Blom H.J., den Heijer M. |
| |
|
ANALYSIS OF MICROPARTICLES IN DEEP VENOUS THROMBOSIS AND ANTIPHOSPHOLIPID SYNDROME PATIENTS AND CARRIERS OF LEIDEN FACTOR V
|
| Flores-Nascimento M.C., Beltrame M.P., Pereira F.G., Lorand-Metze I., Biro E., Berckmans R.J., Nieuwland R., de Paula E.V., Annichino-Bizzacchi J.M. |
| |
|
ANALYSIS OF SURFACE AND SOLUBLE L-SELECTIN IN RELATION TO FLOW CYTOMETRIC PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA
|
| Kiss F., Balogh I., Szasz R., Jako J., Kappelmayer J. |
| |
|
ANALYSIS OF THE GENETIC EXPRESSION OF INFLAMMATORY MEDIATORS IN MONONUCLEAR CELLS FROM DEEP VENOUS THROMBOSIS PATIENTS
|
| Rubin M.S., Deckmann A.C., Carazzolle M.F., Pereira G.A.G., Annichino-Bizzacchi J.M. |
| |
|
ANALYSIS OF THE INTERACTOME IN HUMAN PLATELETS
|
| Dittrich M., Mietner S., Guenther N., Walter U., Dandekar T., Birschmann I. |
| |
|
ANALYSIS OF THE SENSITIVITY OF THE OVERALL HAEMOSTATIC POTENTIAL (OHP) ASSAY TO COAGULATION FACTORS
|
| Curnow J.L., Morel-Kopp M.C., Ward C.M. |
| |
|
ANALYZE OF THE CO-PURIFIED PROTEINS WITH A HIGHLY PURIFIED PLASMA-DERIVED FACTOR VIII: FVIII-SD-35-15
|
| Brandin M., Sauger A., Samor B., Siret L., Michalski C., Chtourou S. |
| |
|
ANAMNESIS IN PATIENTS WITH HEMOPHILIA AND INHIBITORS WHO RECEIVE ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES FOR PROPHYLAXIS
|
| Ewing N.P., Pullens L., De Guzman C. |
| |
|
ANGIOGENESIS IN ENDOMETRIOSIS. INFLUENCE OF THREE FUNCTIONAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS (-460CT, 405GC AND 936CT) IN VEGF EXPRESSION
|
| Cosin R., Gilabert-Estelles J., Ramon L.A., España F., Gilabert J., Castello R., Chirivella M., Estelles A. |
| |
|
ANGIOGENESIS IN RHEUMATOID ARTHRITIS: IS IT RELATED TO ENDOTHELIAL PERTURBATION AND/OR INFLAMMATION?
|
| Blann A.D., Foster W., Carruthers D., Lip G. |
| |
|
ANGIOGENIC GENE THERAPY WITH VASCULAR ENDOTHELIAL GROWTH FACTOR FOR TREATING INTERMITTENT CLAUDICATION
|
| Ojalvo A.G., Gonzalez M.J., Seralena A., Montequin J.F., Reynaldo D., Rochela L., Aldama A., Chirino N., Hernandez A., Hondares M.C., Cabrera J.L., Viñas H., Ponce O., Valdes C., Alvarez H., Barcelona S., Vispo N.S. |
| |
|
ANGIOTENSIN-CONVERTING ENZYME (ACE) INSERTION/DELETION (I/D) POLYMORPHISM AND SERUM LEVELS OF ACE IN VENOUS THROMBOEMBOLISM (VTE)
|
| Ay C., Bencur P., Vormittag R., Sailer T., Jungbauer C., Vukovich T., Mannhalter C., Pabinger I. |
| |
|
ANKLE REPLACEMENT IN SEVERE BLEEDING DISORDERS: RETROSPECTIVE STUDY ON 17 CASES
|
| Rospide P., Asencio J., Di Fazio B., Leonardi C., Polack B., Navarro R., Biron-Andreani C., Schved J. |
| |
|
ANNEXIN 2 AND FIBRINOLYSIS
|
| Hajjar K.A. |
| |
|
ANNEXIN A5 1 C/T POLYMORPHISM DISPLAYS A BETTER OUTCOME IN A LONG TERM FOLLOW-UP AFTER PREMATURE MYOCARDIAL INFARCTION
|
| Roldan V., Marin F., Gonzalez-Conejero R., Corral J., Sandin M., Pineda J., Climent V., Vicente V. |
| |
|
ANOMALOUS BEHAVIOR OF PLATELETS IN RESPONSE TO TEMPERATURE
|
| Maurer-Spurej E. |
| |
|
ANTAGONISM OF INTRINSIC PATHWAY INHIBITS TISSUE FACTOR (TF)-INITIATED COAGULATION IN A PLATELET-DEPENDENT WHOLE BLOOD FLOW ASSAY
|
| Sim D.S., Sinha U., Mann K.G., Phillips D.R., Andre P. |
| |
|
ANTI CD20 MONOCLONAL ANTIBODIES THERAPY FOR RESISTANT ANTIPHOSPHOLIPID SYNDROME
|
| Winder A., Arad A., Rachmilewitz E. |
| |
|
ANTI XA ASSAYS FOR DANAPAROID: ASSESSMENT OF PRE ANALYTICAL AND ANALYTICAL VARIABLES
|
| Wemyss A., Smith J.M., Woolley A., Storr J., Maclean R., Hampton E., Kitchen S. |
| |
|
ANTI-APOPTOTIC EFFECTS OF SERINE PROTEINASES OF HEMOSTASIS AT GLUTAMATE-INDUCED NEUROTOXICITY
|
| Strukova S.M., Gorbacheva L.R., Storojevykh T.P., Pinelis V.G. |
| |
|
ANTIAPOPTOTIC SIGNALING BY TF/FVIIA IS INHIBITED BY SIMVASTATIN
|
| Åberg M., Wickström M., Siegbahn A. |
| |
|
ANTI-BETA 2 GLYCOPROTEIN I ANTIBODIES ASSAYS: USE OF MONOCLONAL ANTIBODIES FOR CALIBRATION
|
| Perucchetti Y., Berruyer M., Ffrench P. |
| |
|
ANTI-CANCER EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN THROMBOSIS-ASSOCIATED TUMOR GROWTH
|
| Mousa S.A., Johansen K.B. |
| |
|
ANTICARDIOLIPIN ANTIBODIES AND OUTCOME OF PREGNANCY A RETROSPECTIVE 3 YEAR STUDY
|
| Ferguson E.J., Laird J., Tait C., Walker I. |
| |
|
ANTI-CD 20 MONOCLONAL ANTIBODY (RITUXIMAB) AS AN OPTIONAL TREATMENT FOR INTRACTABLE ACQUIRED GLANZMANN THROMBASTHENIA
|
| Blickstein D., Lahav J., Molad Y., Shpilberg O., Inbal A. |
| |
|
ANTI-CD3 IN COMBINATION WITH NASAL FVIII-A2 DOMAIN DECREASES FVIII INHIBITORS
|
| Waters B., Labelle A., Burnett E., Thompson P., Qadura M., Ichikawa T., Fay P., Hough C., Lillicrap D. |
| |
|
ANTICOAGULANT EFFECT OF DANAPAROID, FONDAPARINUX, AND LEPIRUDIN IN CHILDREN COMPARED TO ADULTS
|
| Ignjatovic V., Summerhayes R., Yip Y.Y., Monagle P.T. |
| |
|
ANTICOAGULANT HEPARAN SULFATES MODULATE TISSUE REMODELING AT OVULATION
|
| Devantéry C., Dentand I., Day A.J., Shworak N.W., de Agostini A.I. |
| |
|
ANTICOAGULANT MANAGEMENT USING AN INTERNET BASED MONITORING SYSTEM
|
| Harper P.L., Stott S., Ford C., Ngata P. |
| |
|
ANTICOAGULANT PROPERTIES OF HD1, A (PRO)THROMBIN-DIRECTED DNA APTAMER
|
| Kretz C.A., Stafford A.R., Fredenburgh J.C., Weitz J.I. |
| |
|
ANTICOAGULANT RESPONSES IN PATIENTS RECEIVING LOW MOLECULAR WEIGHT HEPARIN COMPARED TO UNFRACTIONATED HEPARIN FOR TEE GUIDED CARDIOVERSION OF ATRIAL FIBRILLATION: RESULTS FROM THE ASSESSMENT OF CARDIOVERSION USING TRANSESOPHAGEAL ECHOCARDIOGRAPHY (ACUTE
|
| Hoppensteadt D., Fareed J., Klein A.K., Jasper S.E., Apperson-Hansen C., Lieber E.A., Katz W., Malouf J.F., Stoddard M.F. |
| |
|
ANTICOAGULATION IN A PATIENT WITH SEVERE PREECLAMPSIA, POSITIVE ANTIBETA2-GLYCOPROTEIN I ANTIBODIES AND HOMOZIGOSITY FOR PAI-1 AND MTHFR
|
| Guglielmone H., Minoldo S., Jarchum G. |
| |
|
ANTICOAGULATION IN CHILDREN WITH DISTAL SPLENORENAL SHUNT (WARREN SHUNT) OR MESENTERICO- LEFT PORTAL SHUNT (REX SHUNT)
|
| Girisch M., Wiegand G., Rauch R. |
| |
|
ANTIDOTE REVERSAL OF A NOVEL ANTICOAGULANT DECREASES MORTALITY AND IMPROVES NEUROLOGICAL FUNCTION IN A MURINE MODEL OF SUBARACHNOID HEMORRHAGE
|
| Blake C.M., Wang H., Laskowitz D.T., Sullenger B.A. |
| |
|
ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) EXPERIENCE ASSESSED THROUGH ONGOING POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS)
|
| Gajek H., Luu H., Ewenstein B., Kriukov A., Barker K., Stephens D., Spotts G. |
| |
|
ANTI-ICOS IMMUNOTHERAPY PREVENTED INHIBITORY ANTIBODY FORMATION AGAINST FACTOR VIII FOLLOWING NONVIRAL GENE TRANSFER IN HEMOPHILIA A MICE
|
| Peng B., Ye P., Blazar B.R., Ochs H.D., Miao C.H. |
| |
|
ANTI-IDIOTYPIC ANTIBODIES FOR THE TREATMENT OF FACTOR VIII INHIBITORS
|
| Saint-Remy J.M. |
| |
|
ANTI-INFLAMMATORY EFFECS OF CLOPIDOGREL IN THE MOUSE
|
| Evangelista V., Dell'Elba G., Martelli N., Amore C., Pecce R., Piccoli A., Manarini S., Totani L. |
| |
|
ANTIINFLAMMATORY EFFECTS OF ARGATROBAN CAN BE DIFFERENTIATED FROM OTHER DIRECT THROMBIN INHIBITORS. EXPERIMENTAL AND CLINICAL OBSERVATIONS
|
| Fareed J., Wahi R., Hoppensteadt D., Bansal V., Walenga J.M., Kaiser B., Bick R. |
| |
|
ANTI-METASTASIS EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN EXPERIMENTAL METASTASIS MODEL
|
| Mousa S.A., Johansen K.B., Francis J.L., Amirkhosravi A. |
| |
|
ANTI-OXIDANTS IMPROVE FACTOR VIII FOLDING AND SECRETION AND REDUCE CELL TOXICITY AND INFLAMMATION IN VIVO IN MICE
|
| Kaufman R.J., Malhotra J., Miao H.Z., Pipe S.W. |
| |
|
ANTI-OXIDANTS IMPROVE FACTOR VIII FOLDING AND SECRETION AND REDUCE CELL TOXICITY AND INFLAMMATION IN VIVO IN MICE
|
| Kaufman R.J., Malhotra J., Pipe S.W., Miao H. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES AND EX-VIVO ENDOTHELIAL PERTURBATION
|
| Mari D., Cugno M., Borghi M.O., Gerosa M., Grossi C., De Angelis V., Magnaghi G., Tincani A., Lonati L., Riboldi P., Meroni P. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH SYSTEMIC LUPUS RYTHMATOSUS
|
| Taouli K., Reghis R.A., Schved S.J.F., Boudghene Stambouli B.O., Hamidou S.R. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES AND TLR2 COLOCALIZED IN HUVEC ENDOSOMES
|
| Satta N., Dunoyer-Geindre S., Fish R.J., Boehlen F., Reber G., Kruithof E.K.O., De Moerloose P. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES ASSOCIATED WITH MULTIPLE COAGULATION FACTOR DEFICIENCY IN SEVEN CHINESE PATIENTS
|
| Yang F., Wang X., Jin P., Ding Q., Wang H. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES DISTURB 2D LATTICE FORMATION OF ANNEXINE A5 ON ACTIVATED PLATELETS
|
| Jacobs N., de Groot P., Hiddink L., Woestenenk R., Boezeman J., van Heerde W.L. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES IN ADULT -THALASSEMIA
|
| Djumhana Atmakusuma T., Reksodiputro A., Tambunan K., Setyaningsih I. |
| |
|
ANTIPHOSPHOLIPID ANTIBODIES SPECTRUM IN WOMEN WITH RECCURENT FETAL LOSS SYNDROME
|
| Baimuradova S.M., Makatsariya A.D., Bitsadze V.O., Akinshina S.V. |
| |
|
ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS): THE ANNEXIN V COMPETITION ASSAY AS A DIAGNOSTIC TOOL
|
| Tomer A. |
| |
|
ANTIPHOSPHOLIPID ANTIBODY SYNDROME IN THE THROMBOPHILIA PILOT PROJECT
|
| Ortel T.L., Beckman M., Dowling N., Bockenstedt P., Manco-Johnson M., James A. |
| |
|
ANTIPHOSPHOLIPID ANTIBODY TESTING IN PIEMONTE AND VALLE D'AOSTA: A MULTILABORATORY EXTERNAL QUALITY ASSURANCE (EQA) PROGRAM
|
| Montaruli B., Vaccarino A., Mengozzi G., Saitta M., Bazzan M. |
| |
|
ANTIPHOSPHOLIPID SYNDROME AND PORTABLE COAGULOMETERS
|
| Barcellona D., Fenu L., Cornacchini S., Marongiu F. |
| |
|
ANTIPLATELET ACTIVITY OF EPIGALLOCATECHIN GALLATE IS MEDIATED BY THE INHIBITION OF PLCGAMMA2 PHOSPHORYLATION, ELEVATION OF PGD2 PRODUCTION AND MAINTENANCE OF CALCIUM-ATPASE PUMP
|
| Jin Y., Cho M., Lee J., Yu J., Im J., Park E., Yoo H., Kim T., Yun Y. |
| |
|
ANTIPLATELET ACTIVITY OF FENOFIBRATE, A PPARALPHA AGONIST, WAS MEDIATED BY BLOCKING OF CYTOSOLIC CALCIUM MOBILIZATION AND THROMBOXANE A2 RECEPTOR
|
| Lee J., Jin Y., Lim Y., Yu J., Lee J., Tudev M., Im J., Park E., Kim T., Lee M., Yun Y. |
| |
|
ANTIPLATELET AND ANTITHROMBOTIC ACTIVITY OF NP-313, 2-ACETYLAMINO-3-CHLORO-1,4-NAPHTHOQUINONE, A NOVEL CPLA2 AND CYTOSOLIC CA 2 + MOBILIZATION INHIBITOR
|
| Kuo H.L., Lien J.C., Kuo S.C., Chung C.H., Chang C.H., Huang T.F. |
| |
|
ANTIPLATELET EFFECTS OF HYDROXYCHAVICOL, A BETEL LEAF COMPONENT
|
| Chang M.C., Jeng J.H. |
| |
|
ANTIPROLIFERATIVE ACTIVITY OF YQN1, A NEWLY SYNTHESIZED INDOLEDIONE DERIVATIVE, ON PDGF-BB-STIMULATED AORTIC VASCULAR SMOOTH MUSCLE CELLS
|
| Yun Y., Seo J., Kim T., Han H., Jin Y., Oh K., Ryu C. |
| |
|
ANTI-PROTEIN S ANTIBODIES IN CHILDREN WITH PURPURA FULMINANS AND IN HEALTHY CHILDREN FOLLOWING VARICELLA AS WELL AS IN CHILDREN WITH THROMBOSIS
|
| Tedgard U., Rask O., Hillarp A., Ljung R. |
| |
|
ANTITHROMBIC EFFECT OF DJW ON PLATELET-ACTIVATING FACTOR-INDUCED PLATELET AGGREGATION
|
| Chang G., Kim J. |
| |
|
ANTITHROMBIN (AT) COMPLEX FORMATION IN BEAGLE DOGS AFTER ADMINISTRATION OF A PHARMACOLOGICAL DOSE OF HUMAN RECOMBINANT FACTOR VIIA (RFVIIA)
|
| Pelzer H., Adam M., Karpf D., Petersen L., Silveira A., Ezban M. |
| |
|
ANTITHROMBIN (AT): A CONFORMATIONAL VARIANT?
|
| Bastos L.A., Blanco A.N., Grosso S.H., Kempfer A.C., Meschengieser S.S., Lazzari M.A. |
| |
|
ANTITHROMBIN CAMBRIDGE II (A384S): AN UNDERESTIMATED GENETIC RISK FACTOR FOR VENOUS THROMBOSIS
|
| Hernandez-Espinosa D., Soria J.M., González-Conejero R., Ordóñez A., González-Porras J.R., Pérez-Ceballos E., Lecumberri R., Sánchez I., Roldán V., Mateo J., Miñano A., González M., Alberca I., Fontcuberta J., Vicente V., Corral J. |
| |
|
ANTITHROMBIN DEFICIENCY IN THE GENERAL POPULATION IS RARELY DUE TO AT GENE MUTATIONS, WHICH ARE MAINLY REPRESENTED BY ALA384SER MUTATION
|
| Giacomelli S.H., Simioni M., Madeo D., Tosetto A., Castaman G., Rodeghiero F. |
| |
|
ANTITHROMBIN III IN COMPARISON WITH FRESH FROZEN PLASMA IN THE TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION ACCOMPANIED BY ANTITHROMBIN III DEFICIENCY
|
| Neporada E.L., Vorobyeva N.A., Turundaevskaya O.V., Melnikova G.N. |
| |
|
ANTITHROMBIN REDUCES COAGULATION AND INFLAMMATION IN A PIG MODEL OF ISLET TRANSPLANTATION
|
| Tournoys A., Jourdain M., Arnalsteen L., Gmyr V., Kerr-Conte J., Pattou F. |
| |
|
ANTITHROMBOTIC ACTIVITIES IN PHARMACOLOGICAL MODELS OF A LONG-ACTING REVERSIBLE SYNTHETIC OLIGOSACCHARIDE
|
| Millet L., Savi P., Herault J., Duchaussoy P., Petitou M., Schaeffer P., Bono F., Herbert J. |
| |
|
ANTITHROMBOTIC ACTIVITY OF THE TP-RECEPTOR ANTAGONIST TERUTROBAN ON FOLTS-LIKE AND FECL3 INDUCED RAT MODELS OF THROMBOSIS
|
| Vallez M., Gaillard F., Lavielle G., Rupin A., Verbeuren T.J. |
| |
|
ANTITHROMBOTIC AND ANTI-PLATELET EFFECTS LIPID-LOWERING DRUGS, HOMOCYSTEINE AND N-METHYLNICOTYNAMIDE PLASMA LEVELS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
|
| Domagala T.B., Dropinski J., Polanski S., Iwaniec T., Kotula-Horowitz K., Szczeklik A. |
| |
|
ANTITHROMBOTIC EFFECT OF ADENOSINTHREEPHOSPHATE AT INTRODUCTION BY AN ANIMALS WITH DISTURB OF HAEMOSTATIC SYSTEM
|
| Lyapina L.A., Pastorova V.E. |
| |
|
ANTITHROMBOTIC EFFECT OF RECOMBINANT DISINTEGRIN IN A MOUSE THROMBOSIS MODEL
|
| Kwack K., Sohn Y., Kim D., Lee S., Chung K. |
| |
|
ANTITHROMBOTIC EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN HYPERCOAGULATION STATES AND CANCER-ASSOCIATED THROMBOSIS
|
| Mousa S.A., Johansen K.B. |
| |
|
ANTITHROMBOTIC PROPHYLAXIS AND THERAPY. THE HUNGARIAN CONSENSUS AND EXPERIENCE, 2007
|
| l. Pfliegler on Behalf of the Hungarian Consensus Conference G.P. |
| |
|
ANTITHROMBOTIC THERAPY AND SURGERY
|
| Samama C.M. |
| |
|
ANTITHROMBOTIC THERAPY IN INFANTS WITH SVC SYNDROME: ADDITIONAL MODALITIES ARE REQUIRED
|
| Yee D.L., Davenport J.J., Justino H., Mahoney D.H. |
| |
|
ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS
|
| Iorio A., Marchesini E., Agnelli G. |
| |
|
ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIACS AN UPDATE OF 14 YEARS EXPERIENCE IN A PRIVATE PRACTICE CCC
|
| Koehler-Vajta K.E., Froesner G., Zachoval R. |
| |
|
APIXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR: MULTIPLE-DOSE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN HEALTHY SUBJECTS
|
| Frost C., Yu Z., Moore K., Nepal S., Barrett Y., Mosqueda-Garcia R., Shenker A. |
| |
|
APIXABAN, AN ORAL DIRECT, FACTOR XA INHIBITOR: SINGLE-DOSE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY SUBJECTS
|
| Frost C., Yu Z., Nepal S., Mosqueda-Garcia R., Shenker A. |
| |
|
APO B ECORI AND INSERTION/DELETION POLYMORPHISMS IN BRAZILIAN YOUNG PATIENTS WITH ISQUEMIC STROKE
|
| Santos C.G.M., Carvalho M.G., Sabino A.P., Ribeiro D.D., Dusse L.M.S., Fernandes A.P.S.M. |
| |
|
APOA1 PROMOTER POLYMORPHISMS AND THEIR ASSOCIATION WITH LIPOPROTEINS IN ASIAN INDIAN FAMILIES WITH CORONARY ARTERY DISEASE (CAD)
|
| Shanker J., Ganapathy P., Rao V., Natesha B.K., Mukherjee M., Kakkar V.V. |
| |
|
APOB/APOA-I RATIO IN PATIENTS WITH ISCHEMIC STROKE (IS) AND PERIPHERAL ARTERIAL DISEASE
|
| Sabino A.P., Carvalho M.G., Ribeiro D.D., Lima L.M., Sousa M.O., Domingheti C.P., Dusse L.M.S., Fernandes A.P.S.M. |
| |
|
APOE GENE POLYMORPHISM CAN MODIFY THE RISK OF VENOUS THROMBOEMBOLISM
|
| Kapustin S.I., Drizhun Y.S., Shmeleva V.M., Saltykova N.B., Papayan L.P., Blinov M.N. |
| |
|
APOLIPOPROTEIN A1 AS A PREDICTOR OF RECURRENT VENOUS THROMBOSIS. RESULTS OF A PLASMA PROTEOMICS APPROACH
|
| den Heijer M., Loof A., van Tits B.L.J., van Heerde W.L. |
| |
|
APPLICABILITY OF A THROMBIN GENERATION TEST IN LABORATORY SCREENING
|
| King V., Grimm L., Pusateri A.E. |
| |
|
APPLICABILITY OF D-DIMER IN RULING OUT VENOUS THROMBOEMBOLISM (VTE) IN ELDERLY MEDICAL PATIENTS: COMPARISON BETWEEN IMMUNOTURBIDIMETRIC AND ELISA (ELFA) METHODS
|
| Antonelli F., Masotti L., Villani L., Landini G. |
| |
|
APPLICATION OF AUTOLOGOUS RED BLOOD CELLS CONCENTRATE DERIVED FROM UMBILICAL CORD BLOOD FOR THERAPY OF ANAEMIC NEONATES
|
| Appaloop M.V., Veryasov V.N., Foteeva T.S., Baibarina E.N. |
| |
|
APPLICATION OF DISCRETE PLASMAPHERESIS IN TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME
|
| Vorobyeva N.A., Turundaevskaja O.V. |
| |
|
APPLICATION OF LOW MOLECULAR-WEIGHT HEPARIN (NARDROPARINE) IN PATIENTS WITH LUNG CANCER
|
| Vorobiova E.E.V., Akhvlediani M.M.A., Pargalava N.N.P., Gagua R.R.G., Aloeva M.M.A. |
| |
|
APPLICATION OF PROTEOMICS TO THE IDENTIFICATION OF PROTEINS ASSOCIATED WITH THE PLATELET STORAGE LESION AND THEIR TRANSLATION
|
| Thon J.N., Schubert P., Serrano K., Kast J., Devine D.V. |
| |
|
APPLICATION OF THREE SEPARATE CVD PREDICTIVE SCORES AND THE RELEVANCE OF NOVEL BIOMARKERS TO RISK STRATIFICATION OF ASIAN INDIANS USING THE FRAMINGHAM RISK SCORE
|
| Kanjilal S., Rao V.S., Mukherjee M., Natesha B.K., Renuka K.S., Sibi K., Iyengar S.S., Kakkar V.V. |
| |
|
APPROACH TO THE DIAGNOSIS AND MANAGEMENT OF MILD BLEEDING DISORDERS
|
| Greaves M., Watson H.G. |
| |
|
AQUAPORIN 2 GENE VARIATIONS, LEVELS OF VON WILLEBRAND FACTOR AND FACTOR VIII AND THE RISK OF VENOUS THROMBOSIS
|
| Nossent A.Y., Eikenboom J.C.J., Vos H.L., Bertina R.M., Rosendaal F.R. |
| |
|
ARE ANTIPHOSPHOLIPID ANTIBODIES RISK FACTORS FOR CORONARY ARTERY DISEASE?
|
| Greco T.P., Conti-Kelly A., Matsuura E., Greco Jr T., Dier K.J., Svanas G., Doyle R., Lopez L.R. |
| |
|
ARE PATIENTS WITH THROMBOPHILIA AND A HISTORY OF VENOUS THROMBOEMBOLISM AT HIGHER RISK TO ARTERIAL THROMBOTIC EVENTS?
|
| Linnemann B., Schindewolf M., Zgouras D., Erbe M., Jarosch-Preusche M., Luxembourg B., Lindhoff-Last E. |
| |
|
ARE VASCULAR ENDOTHELIAL GROWTH FACTOR PLASMA LEVELS A PREDICTIVE MARKER OF SUNITINIB RESPONSE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA?
|
| Helley D., Thiam R., Bouziane A., Ebenezer C., Fournier L., Balvay D., Cuenod C.A., Oudard S., Fischer A.M. |
| |
|
ARGATROBAN DOSE REQUIREMENTS IN INTENSIVE CARE UNIT PATIENTS
|
| Smythe M.A., Mattson J.C., Kennedy M., Koerber J.M. |
| |
|
ARGATROBAN IN PATIENTS AFTER CARDIOVASCULAR SURGERY: INFLUENCE ON A THROMBIN GENERATION ASSAY
|
| Harder S., Merz M., Koster A. |
| |
|
ARGATROBAN IS CAPABLE OF PASSING THROUGH THE BLOOD BRAIN BARRIER. POTENTIAL IMPLICATIONS IN THE MANAGEMENT OF THROMBOTIC STROKE
|
| Fareed J., Hoppensteadt D., Maddineni J., Kaiser B., Walenga J.M. |
| |
|
ARGININE THERAPY TENDS TO REDUCE ENDOTHELIAL DAMAGE IN SEPSIS
|
| Govers-Riemslag J.W.P., Curvers J., Magdeleyns E.J.P., Luiking Y.C., Deutz N.E.P., ten Cate H. |
| |
|
ARTERIAL STIFFNESS, ENDOTHELIAL FUNCTION AND THE RISK OF ISCHAEMIC STROKE
|
| Ford I., Mackay I., Kalal K.K., Greaves M., Brittenden J. |
| |
|
ARTERIOVENOUS FISTULA (AVF) IS A SAFE AND SUITABLE VENOUS ACCESS FOR IMMUNE TOLERANCE TREATMENT (ITT) IN HEMOPHILIC CHILDREN
|
| Santagostino E., Mancuso M.E., Siboni S.M., Mannucci P.M. |
| |
|
ASPIRIN EFFICACY: ANALYSIS OF WHOLE BLOOD-AGGREGATION USING THE SCREEN FILTRATION PRESSURE METHOD
|
| Kondo H., Tabuchi A., Taniguchi R., Kawato M., Ikeda T., Morimoto T., Kita T., Horiuchi H. |
| |
|
ASPIRIN PREVENTS PLATELET ACTIVATION AFTER CORONARY ARTERY BYPASS SURGERY DESPITE AN INCREASE IN THROMBOXANE A2 SYNTHESIS
|
| Favreau F., Jayle C., Bosc L., Christiaens L., Macchi L. |
| |
|
ASPIRIN-RESISTANCE IN CHILDREN
|
| Rauch R., Wiegand G., Stellos K., Girisch M., Hofbeck M., Gawaz M. |
| |
|
ASSAY DEVELOPMENT FOR PLASMA FACTOR VIIA-ANTITHROMBIN COMPLEX (FVIIA-AT)
|
| Adam M., Vauthier C., Morrissey J., Woodhams B.J. |
| |
|
ASSESSMENT OF A METHOD BASED ON LUMINESCENCE DETECTION FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Granjon S., Rugeri L., Bordet J., Mazet M., Négrier C. |
| |
|
ASSESSMENT OF ACTIONS FOR IMPROVING PREVENTION OF THROMBOEMBOLIC DISEASE IN MEDICAL PATIENTS
|
| Khayat G.R., Ibrahim I., Baaklini C., Khayat C. |
| |
|
ASSESSMENT OF CLOT LYSIS TIME TISSUE FACTOR-INDUCED BY EXOGENOUS T-PA IN HEALTHY SUBJECTS BY USING A MICROPLATE READER
|
| Cellai A., Lami D., Paniccia R., Bandinelli B., Alessandrello Liotta A., Fedi S., Abbate R., Gensini G., Prisco D. |
| |
|
ASSESSMENT OF PLATELET FUNCTION IN NORMAL ADULTS: RISTOCETIN-INDUCED PLATELET AGGREGATION (RIPA)
|
| Stein S.F., Rice A., Lindstrom K., Miller C.H. |
| |
|
ASSESSMENT OF PLATELET P2Y1 FUNCTION IN CLOPIDOGREL-TREATED ISCHEMIC HEART DISEASE PATIENTS
|
| Toth-Zsamboki E., Beres B., Vargova K., Kiss N., Kerecsen G., Preda I., Kiss R. |
| |
|
ASSESSMENT OF THE EFFECTIVENESS AND SECURITY OF HOME TREATMENT OF DEEP VENOUS THROMBOSIS WITH LOW MOLECULAR WEIGHT HEPARIN IN ARGENTINA
|
| Tacchi M.C., Du |
